Restricted accessResearch articleFirst published online 2025
Development and Validation of Overall Survival and Amputation-Free Survival Prediction Models for Patients with Peripheral Arterial Disease Who underwent Endovascular Therapy
To identify the most valuable predictor associated with overall survival (OS) and amputation-free survival (AFS) and to develop and validate OS and AFS prediction models for patients with peripheral arterial disease (PAD) who underwent endovascular therapy (EVT).
Methods:
This study included patient with PAD who EVT between January 2018 to June 2023 across 3 hospitals in southwest China. Outcomes were OS and AFS at 1, 2, and 3 years.
Results:
A total of 2792 consecutive patients with PAD who underwent EVT were included, with an average follow-up period was 14.0 ± 8.7 months. During the follow-up period, 412 (14.8%) patients died, and 737 (26.4%) patients experienced either amputation or death. The OS rates in 1-, 2-, and 3-years were 89.3%, 81.2%, and 74.2% in the whole cohort, respectively. In terms of AFS, the rates at 1-, 2-, and 3-years were 81.7%, 68.3%, and 54.1%, respectively. Predictors in the OS prediction model included age, diabetes mellitus (DM), body mass index (BMI) classification, dialysis-dependent renal failure (DRF), Rutherford classification, antiplatelet therapy, and cilostazol therapy (p < 0.05). Predictors in the AFS prediction model included DM, chronic obstructive pulmonary disease, DRF Rutherford classification, antiplatelet therapy, and cilostazol therapy (p < 0.05). The area under the curve and calibration curves for training, internal, and external validation of both OS and AFS prediction models indicated good performance.
Conclusions:
This study demonstrates that both OS and AFS prediction models exhibit good discriminative ability to predict survival rate and AFS rate in patients with PAD. PAD patients with DM, DRF, Rutherford classification R5 and R6, absence of antiplatelet, and cilostazol therapy were associated with significantly lower OS and AFS rates. Controlling these risk predictors may be guide patient care in clinical settings.
Clinical Impact
In this multicenter longitudinal study, 2792 patients were included in the overall survival (OS) and amputation-free survival (AFS) prediction models development and validation. Patients with modifiable risk factors could potentially benefit from strategies aimed at preventing disease process (Rutherford classification), controlling comorbidities (diabetes mellitus, chronic obstructive pulmonary disease, and dialysis-dependent renal failure), and enhancing adherence to medical therapy (antiplatelet and cilostazol therapy). Our models have ability to predict survival and AFS rates at multiple time points, thereby facilitating early identification of high-risk patients and enabling timely interventions to optimize patient outcomes.
BevanGHSolaruKTW. Evidence-based medical management of peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40:541–553.
2.
SpannbauerAChwalaMRidanT, et al. Intermittent claudication in physiotherapists’ practice. Biomed Res Int. 2019;2019:2470801.
3.
MuellerLEngelbertzCReineckeH, et al. Secondary prevention in lower extremity artery disease patients: lipid-lowering therapy and long-term guideline adherence. J Clin Med. 2022;11:1–14.
4.
AitkenSJ.Peripheral artery disease in the lower limbs: the importance of secondary risk prevention for improved long-term prognosis. Aust J Gen Pract. 2020;49:239–244.
5.
ZhangDLiYKalbaughCA, et al. Machine learning approach to predict in-hospital mortality in patients admitted for peripheral artery disease in the United States. J Am Heart Assoc. 2022;11:e026987.
6.
Report on Cardiovascular Health and Diseases in China 2021: an updated summary. Biomed Environ Sci. 2022;35:573–603.
7.
NorgrenLHiattWRDormandyJA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33:S5–S75.
8.
UrbanoLPortillaEMunozW, et al. Prevalence and risk factors associated with peripheral arterial disease in an adult population from Colombia. Arch Cardiol Mexico. 2018;88:107–115.
MatsushitaKSangYNingH, et al. Lifetime risk of lower-extremity peripheral artery disease defined by Ankle-Brachial Index in the United States. J Am Heart Assoc. 2019;8:e012177.
11.
DemsasFJoinerMMTelmaK, et al. Disparities in peripheral artery disease care: a review and call for action. Semin Vasc Surg. 2022;35:141–154.
12.
Martins CuryMVBrochado NetoFCMatieloMF, et al. Evaluation of the BASIL survival prediction model in patients undergoing infrapopliteal interventions for critical limb ischemia. Ann Vasc Surg. 2019;55:85–95.
13.
LiuYXueJJiangJ.Application of machine learning algorithms in electronic medical records to predict amputation-free survival after first revascularization in patients with peripheral artery disease. Int J Cardiol. 2023;383:175–184.
14.
RichterLFreisingerELuedersF, et al. Impact of diabetes type on treatment and outcome of patients with peripheral artery disease. Diab Vasc Dis Res. 2018;15:504–510.
15.
WitrickBKalbaughCAMayoR, et al. Disparities in healthcare utilization by insurance status among patients with symptomatic peripheral artery disease. BMC Health Serv Res. 2023;23:913.
16.
SogaardMNielsenPBSkjothF, et al. Temporal changes in secondary prevention and cardiovascular outcomes after revascularization for peripheral arterial disease in Denmark: a nationwide cohort study. Circulation. 2021;143:907–920.
17.
VerwerMCWijnandJGJTeraaM, et al. External validation of the Vascular Quality Initiative prediction model for survival in no-option chronic limb-threatening ischemia patients. J Vasc Surg. 2020;72:1659–1666.
18.
DjerfHMillingerJFalkenbergM, et al. Absence of long-term benefit of revascularization in patients with intermittent claudication five-year results from the IRONIC Randomized Controlled Trial. Circ Cardiovasc Interv. 2020;13:1–106.
19.
NorvellDCThompsonMLBoykoEJ, et al. Mortality prediction following non-traumatic amputation of the lower extremity. Br J Surg. 2019;106:879–888.
20.
SimonsJPSchanzerAFlahiveJM, et al. Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. J Vasc Surg. 2019;69:S120–S134.
21.
MiyataTKumamaruHMiiS, et al. Prediction models for two year overall survival and amputation free survival after revascularisation for chronic limb threatening ischaemia. Eur J Vasc Endovasc Surg. 2022;64:367–376.
22.
RoijersJPRakkeYSHopmansCJ, et al. A mortality prediction model for elderly patients with critical limb ischemia. J Vasc Surg. 2020;71:2065–2072.e2.
23.
AboyansVRiccoJ-BBartelinkM-LEL, et al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:301–302.
24.
CollinsGSReitsmaJBAltmanDG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;7:7594.
25.
CronenwettJLJohnstonKW.Rutherford Vascular Surgery. Peking University Medical Press; 2013.
26.
RileyRDEnsorJSnellKIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;18:441.
27.
WismanPPvan HattumESvan der GraafY, et al. Risk chart for future mortality and ischaemic events following peripheral bypass surgery. Eur J Vasc Endovasc Surg. 2015;50:87–93.
28.
HigashitaniMUemuraYMizunoA, et al. Cardiovascular outcome and mortality in patients undergoing endovascular treatment for symptomatic peripheral artery disease—short-term results of the Toma-Code Registry. Circ J. 2018;82:1917–1925.
29.
TernPJWKujawiakISahaP, et al. Site and burden of lower limb atherosclerosis predicts long-term mortality in a cohort of patients with peripheral arterial disease. Eur J Vasc Endovasc Surg. 2018;56:849–856.
30.
CoxMPanagidesJCTabariA, et al. Risk stratification with explainable machine learning for 30-day procedure-related mortality and 30-day unplanned readmission in patients with peripheral arterial disease. PLoS One. 2022;17:e0277507.
31.
HackGBelajKGaryT, et al. COPART risk score predicts long-term mortality in peripheral arterial occlusive disease. Eur J Vasc Endovasc Surg. 2015;50:94–100.
32.
JonesWSPatelMRTsaiTT, et al. Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. Am Heart J. 2015;170:400-U273.
33.
DopheideJFRamadaniHAdamL, et al. Development of a 3-dimensional prognostic score for patients with symptomatic peripheral artery disease: PAD3D Score. Angiology. 2020;71:658–665.
34.
RuangsetakitChanean NSanitP, et al. The Geriatric Nutritional Risk Index predicts amputation after infrapopliteal angioplasty in critical limb ischemia patients. Asian J Surg. 2023;46:250–253.
35.
KinlayS.Management of critical limb ischemia. Circ Cardiovasc Interv. 2016;9:1–23.
36.
GolledgeJCroninOIyerV, et al. Body mass index is inversely associated with mortality in patients with peripheral vascular disease. Atherosclerosis. 2013;229:549–555.
37.
WischmeyerPECarliFEvansDC, et al. American Society for Enhanced Recovery and Perioperative Quality Initiative Joint Consensus Statement on nutrition screening and therapy within a surgical enhanced recovery pathway. Anesth Analg. 2018;126:1883–1895.
38.
AmrockSMAbrahamCZJungE, et al. Risk factors for mortality among individuals with peripheral arterial disease. Am J Cardiol. 2017;120:862–867.
39.
LapebieF-XBongardVLacroixP, et al. Mortality, cardiovascular and limb events in patients with symptomatic lower extremity artery disease and diabetes. Angiology. 2022;73:528–538.
40.
OnofreiVACeasovschihAMarcuDTM, et al. Mortality risk assessment in peripheral arterial disease—the burden of cardiovascular risk factors over the years: a single center’s experience. Diagnostics. 2022;12:2499.
41.
MuellerTHinterreiterFLuftC, et al. Mortality rates and mortality predictors in patients with symptomatic peripheral artery disease stratified according to age and diabetes. J Vasc Surg. 2014;59:1291–1299.
42.
TakaharaMKanetoHIidaO, et al. The influence of glycemic control on the prognosis of japanese patients undergoing percutaneous transluminal angioplasty for critical limb ischemia. Diabetes Care. 2010;33:2538–2542.
43.
Gerhard-HermanMDGornikHLBarrettC, et al. 2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:E686–E725.
44.
FrankUNikolSBelchJ, et al. ESVM Guideline on peripheral arterial disease. Vasa-Eur J Vasc Med. 2019;48:7–79.
45.
VisserenFLJMachFSmuldersYM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42:3227–3337.
46.
AliTZLehmanEBAzizF.Modified frailty index can be used to predict adverse outcomes and mortality after lower extremity bypass surgery. Ann Vasc Surg. 2018;46:168–177.
47.
GuptaPKRamananBLynchTG, et al. Development and validation of a risk calculator for prediction of mortality after infrainguinal bypass surgery. J Vasc Surg. 2012;56:372–379.
48.
BrothersTEZhangJMauldinPD, et al. Predicting outcomes for infrapopliteal limb-threatening ischemia using the Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg. 2016;63:114-U183.
49.
Takeji YasuakiYKyoheiT, et al. Impact of frailty on clinical outcomes in patients with critical limb ischemia. Circ Cardiovasc Interv. 2018;11:e006778.
50.
SarehSohail URamseyD, et al. Impact of frailty on clinical and financial outcomes following minor lower extremity amputation: a nationwide analysis. Am Surg. 2020;86:1312–1317.
51.
LiJun AShilpkumarI, et al. The utility of geriatric nutritional risk index to predict outcomes in chronic limb-threatening ischemia. Catheter Cardiovasc Interv. 2022;99:121–133.
52.
ShahKBElzeneiniMShahSK, et al. Social vulnerability is associated with higher rates of hospitalizations and amputations for peripheral arterial disease. Am J Cardiol. 2023;203:463–465.
53.
GonzalezLorena KMohammedO, et al. Frailty and biomarkers of frailty predict outcome in veterans after open and endovascular revascularization. J Surg Res. 2019;243:539–552.
54.
GiannopoulosSMustaphaJGrayWA, et al. Three-year outcomes from the LIBERTY 360 study of endovascular interventions for peripheral artery disease stratified by Rutherford Category. J Endovasc Ther. 2021;28:262–274.
55.
IidaONakamuraMYamauchiY, et al. 3-Year outcomes of the OLIVE Registry, a prospective multicenter study of patients with critical limb ischemia a prospective, multi-center, three-year follow-up study on endovascular treatment for infra-inguinal vessel in patients with critical limb ischemia. JACC Cardiovasc Interv. 2015;8:1493–1502.
56.
ChaJ-JKimJ-YKimH, et al. Long-term clinical outcomes and prognostic factors after endovascular treatment in patients with chronic limb threatening ischemia. Korean Circ J. 2022;52:429–440.
57.
BeckmanJACreagerMA.Critical limb ischemia and intermediate-term survival. JACC Cardiovasc Interv. 2014;7:1450–1452.
58.
PanDWangJGuoJ, et al. Impact of geriatric nutritional risk index on prognosis in peripheral artery disease patients undergoing endovascular therapy. J Clin Hypertens. 2023;25:497–503.
59.
ProsNCambouJPAboyansV, et al. A hospital discharge risk score for 1-year all-cause mortality or non-fatal cardiovascular events in patients with lower-extremity peripheral artery disease, with and without revascularisation. Eur J Vasc Endovasc Surg. 2013;45:488–496.
60.
CatalanoMBornGPetoR.Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med. 2007;261:276–284.
61.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
62.
BjorckMEarnshawJJAcostaS, et al. Editor’s choice—European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of acute limb ischaemia. Eur J Vasc Endovasc Surg. 2020;59:173–218.
63.
Vascular Surgery Group SSoCMA. Guidelines for diagnosis and treatment of lower extremity arteriosclerosis obliterans. Chin Arch Gen Surg. 2016;10:1–18.
64.
MachFBaigentCCatapanoAL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–188.
65.
CosentinoFGrantPJAboyansV, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
66.
RossiMIezziR.Cardiovascular and interventional radiological society of Europe Guidelines on endovascular treatment in aortoiliac arterial disease. Cardiovasc Intervent Radiol. 2014;37:13–25.
67.
NoharaRAdachiHGotoY, et al. Guidelines for rehabilitation in patients with cardiovascular disease (JCS 2012)—digest version. Circ J. 2014;78:2022–2093.
68.
BedenisRStewartMCleanthisM, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. 2014;2014:Cd003748.
69.
BonacaMPHamburgNMCreagerMA.Contemporary medical management of peripheral artery disease. Circ Res. 2021;128:1868–1884.
70.
NarulaNDannenbergAJOlinJW, et al. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol. 2018;72:2152–2163.
71.
IidaOYokoiHSogaY, et al. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the sufficient treatment of peripheral intervention by cilostazol study. Circulation. 2013;127:2307–2315.
72.
IkushimaIYonenagaKIwakiriH, et al. A better effect of cilostazol for reducing in-stent restenosis after femoropopliteal artery stent placement in comparison with ticlopidine. Med Devices (Auckland). 2011;4:83–89.
73.
NantoKIidaOTakaharaM, et al. Effect of cilostazol following endovascular intervention for peripheral artery disease. Angiology. 2015;66:774–778.
74.
GalyfosGChamzinASaliarisK, et al. The effect of cilostazol on late outcomes after endovascular treatment for occlusive femoropopliteal disease. J Vasc Surg. 2024;80:279–287.
75.
AlameddineDDamaraFARodriguezPP, et al. The use and impact of cilostazol on patients undergoing endovascular peripheral interventions. Ann Vasc Surg. 2024;103:47–57.
76.
Butala NeelMRAishwaryaX, et al. Association of frailty with treatment selection and long-term outcomes among patients with chronic limb-threatening ischemia. J Am Heart Assoc. 2021;10:e023138.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
